CARDIOVASCULAR COMPLICATIONS OF DIABETES MELLITUS: PATHOPHYSIOLOGY, CLINICAL MANIFESTATIONS, AND MODERN THERAPEUTIC STRATEGIES
Keywords:
Diabetes mellitus, cardiovascular disease, atherosclerosis, diabetic cardiomyopathy, hypertension, endothelial dysfunction, chronic inflammation, hyperglycemia, therapeutic approaches, public health.Abstract
This article is based on the analysis of modern scientific publications devoted to the pathophysiological basis of diabetes mellitus, its direct impact on the cardiovascular system, and the development of related chronic diseases. Particular attention is paid to the molecular and hemodynamic mechanisms of diabetic cardiovascular dysfunction, hyperglycemia-induced vascular injury, and the potential application of advanced preventive and therapeutic approaches in the healthcare system of the Republic of Uzbekistan.
References
1. American Heart Association. Circulation: Cardiovascular Quality and Outcomes. Guidelines on Diabetes and Heart Disease. 2021.
2. Rydén L, Grant PJ, Anker SD, et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases. European Heart Journal. 2013;34(39):3035-3087.
3. Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circulation Research. 2018;122(4):624-638.
4. Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2018;379(7):633-644.
5. Paneni F, Beckman JA, Creager MA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. European Heart Journal. 2013;34(31):2436-2443.
6. Rosano GM, Vitale C, Seferovic P. Heart failure in patients with diabetes mellitus. Cardiac Failure Review. 2017;3(1):52-55.
7. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. New England Journal of Medicine. 2015;373(22):2117-2128.
8. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006;444(7121):860-867.
9. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. New England Journal of Medicine. 2016;375(4):311-322.
10. Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: cardiovascular disease in diabetes mellitus. Circulation. 2016;133(24):2459-2502.
11. Vinik AI, Ziegler D. Diabetic cardiovascular autonomic neuropathy. Circulation. 2007;115(3):387-397.
12. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New England Journal of Medicine. 2017;377(7):644-657.
